Novartis Institutes for BioMedical Research Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Novartis Institutes for BioMedical Research Inc.
David Reese, chief technology officer and former EVP of R&D, and newly appointed EVP of R&D Jay Bradner spoke with Scrip about how Amgen is pairing artificial intelligence with genomics plus data milestones in 2024.
Amgen appointed R&D head David Reese as EVP and chief technology officer and recruited former Novartis executive Jay Bradner as EVP of R&D and chief scientific officer.
Despite the growing interest, both in and outside of the biotech space, in the so-called ‘longevity’ industry, no regulatory pathway exists to market a drug with a purely geroprotective indication.
The French drugmaker has begun an external and internal search to succeed John Reed who is heading for Johnson & Johnson after an up-and-down five years as Sanofi’s R&D chief.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.